HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
After SpringWorks, Immunome has a Ringside seat
Varegacestat’s pivotal study reads out imminently.
The month ahead: December’s upcoming events
ASH and SABCS approach.
BioNTech’s big gotistobart day approaches
Readout of the Preserve-003 trial in post-PD-(L)1 NSCLC is due in December.
ASH 2025 preview – toxicity worries hit BeOne’s sonrotoclax
The project has priority review, but deaths could raise eyebrows.
Kivu and Menarini against the odds
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
ASH 2025 preview – a new menin battleground
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
ASH 2025 preview – another degrader fight
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
ASH 2025 preview – multiple myeloma focus
Arcellx and AstraZeneca take centre stage.
